medigraphic.com
ISSN 1028-4818 (Electronic)

2014, Number 1

<< Back Next >>

Mul Med 2014; 18 (1)

New therapeutic options for Disorders Movement in Parkinson’s disease

Piña TAA

Language: Spanish
References: 43
Page:
PDF size: 355.68 Kb.


ABSTRACT

Movement Disorders, such as Parkinson’s disease, tremor, and dystonia, are among the most common neurological conditions and affect millions of patients. Although medications are the mainstay of therapy for movement disorders, neurosurgery has played an important role in their management for the past 50 years. Surgery is now a viable and safe option for patients with medically intractable Parkinson’s disease, essential tremor, and dystonia. The field of functional neurosurgery has witnessed a renaissance over the past 20 years. This development has been fueled by progress in the neurobiology of movement disorders, surgical technical advancements, therapeutic device developments and innovative approaches. The growth in our understanding of the neural circuitry of the disease has determined and refined our surgical targets and will guide the discovery of additional targets for surgical exploration and clinical research. The evolution of stereotactic surgical tools and techniques is facilitating safe and minimally invasive approaches that enable neurosurgeons to target various brain structures with reliable accuracy. This coupled with rapid advances in imaging technology and capabilities, will play an important role in improving our capability to visualize brain structures and function with unparalleled resolution. The lessons learned from movement-disorder surgical experience are already being applied to surgical treatment of psychiatric and other chronic neurological disorders.


REFERENCES

  1. How common are the “common” neurologic disorders? Neurology January 30, 2007 68:326-337.

  2. Dorsey ER, Constantinescu R, Thompson JP, Biglan KM, Holloway RG, Kieburtz K, et al. Projected number of people with Parkinson disease in the most populous nations, 2005 through 2030. Neurology 2007; 68:384-386.

  3. Neurologist care in Parkinson disease: A utilization, outcomes, and survival study Neurology August 30, 2011 77:851-857; published ahead of print August 10, 2011.

  4. Projecting neurologic disease burden: Difficult but critical. Neurology. 2007; 68:322-3.

  5. Tolosa E, Wenning G, Poewe W. The diagnosis of Parkinson’s disease. Lancet Neurology. 2006; 5(1):75–86.

  6. Parkinson J. An Essay on the Shaking Palsy. London: Sherwood, Neely, and Jones; 1817.

  7. Lang A. Parkinsonism. In: Goldman L, Ausiello D, eds. Cecil Medicine. 23rd ed. Philadelphia, Pa: Saunders Elsevier; 2007: chap 433.

  8. Rodríguez-Oroz M.C., Blesa F.J., Benítez-Temino B. Guridi J., Rodríguez M. Obeso J. A. Denervación dopaminérgica y fisiopatología de los ganglios basales. Neurol Supl 2007; 3(5): 32-41.

  9. Pavese N, Kiferle L, Piccini P. Neuroprotection and imaging studies in Parkinson’s disease. Parkinsonism and Related Disorders. 2010; 15(4):S33–S37.

  10. Pahwa R, Lyons KE. Early diagnosis of Parkinson’s disease: recommendations from diagnostic clinical guidelines. The American Journal of Managed Care. 2010; 16:S94–99.

  11. Fung HC, Scholz S, Matarin M, Simon-Sanchez J, Hernandez D, Britton A, et al. Genome-wide genotyping in Parkinson's disease and neurologically normal controls: first stage analysis and public release of data. Lancet Neurology 2006; 5 (11); 911-916.

  12. Weng YH, Chou YHW, Wu WS, et al. PINK1 mutation in Taiwanese early-onset parkinsonismml: clinical, genetic, and dopamine transporter studies. Journal of Neurology. 2007; 254(10):1347–1355.

  13. Associated factors for REM sleep behavior disorder in Parkinson disease Neurology September 13, 2011 77:1048-1054; published ahead of print August 10, 2011.

  14. Methylphenidate for gait impairment in Parkinson disease: A randomized clinical trial / / Neurology December 6, 2011 77:e140.

  15. Lang A. Other movement disorders. In: Goldman L, Ausiello D, eds. Cecil Medicine. 23rd ed. Philadelphia, Pa: Saunders Elsevier; 2007: chap 434.

  16. Mild cognitive impairment in drug-naive patients with PD is associated with cerebral hypometabolism Neurology October 4, 2011 77:1357-62.

  17. Levodopa toxicity and Parkinson disease: Still a need for equipoise Neurology October 11, 2011 77:1416-1417; published ahead of print September 14, 2011,

  18. Is levodopa toxic?: Insights from a brain bank Neurology October 11, 2011 77:1414-1415; published ahead of print September 14, 2011.

  19. Rajabally YA, Martey J. Neuropathy in Parkinson disease: prevalence and determinants. Neurology 2011; 77:1947–1950.

  20. Toth C, Brown MS, Furtado S, Suchowersky O, Zochodne D. Neuropathy as a potential complication of levodopa use in PD’s disease. Mov Disord 2008;23:1850–1859.

  21. Diem-Zangerl A, Seppi K. Neuropathy as a potential complication of levodopa use in Parkinson’s disease: a pharmacological and pharmacovigilance point of view. Mov Disord 2010; 25:659–664.

  22. Grafton ST, Turner RS, Desmurget M, Bakay R, Delong M, Vitek J, et al. Normalizing motor-related brain activity: subthalamic nucleus stimulation in Parkinson disease. Neurology 2006; 66 (8); 1192-1199.

  23. Sioka C, Fotopoulos A, Kyritsis AP. Recent advances in PET imaging for evaluation of Parkinson’s disease. European Journal of Nuclear Medicine and Molecular Imaging. 2010; 37:1594–1603.

  24. Brooks DJ, Frey KA, Marek KL, et al. Assessment of neuroimaging techniques as biomarkers of the progression of Parkinson’s disease. Experimental Neurology. 2003; 184(1):S68–S79.

  25. Pavese N, Brooks DJ. Imaging neurodegeneration in Parkinson’s disease. Biochimica et Biophysica Acta. 2009;1792(7):722–729.

  26. Antonini A. Imaging for early differential diagnosis of parkinsonism. TheLancetNeurology. 2010; 9(2):130–131.

  27. Uc EY, Follett KA: Deep brain stimulation in movement disorders. Semin Neurol 27:170–182, 2007.

  28. Okun MS, Rodriguez RL, Mikos A, Miller K, Kellison I, Kirsch-Darrow L, Wint DP, Springer U, Fernandez HH, Foote KD, Crucian G, Bowers D: Deep brain stimulation and the role of the neuropsychologist. Clin Neuropsychol 21:162–189, 2007.

  29. Vesper J, Haak S, Ostertag C, Nikkhah G: Subthalamic nucleus deep brain stimulation in elderly patients—Analysis of outcome and complications. BMC Neurol 7:7, 2007.

  30. Applications for the Surgery.VOLUME 62 | NUMBER 2 | FEBRUARY 2008 SUPPLEMENT | SHC715

  31. Kaplitt MG, Feigin A, Tang C, Fitzsimons HL, Mattis P, Lawlor PA, Bland RJ, Young D, Strybing K, Eidelberg D, During MJ: Safety and tolerability of gene therapy with an adeno-associated virus (AAV) borne GAD gene for Parkinson’s disease: An open label, phase I trial. Lancet 2007; 369(9579):2097–2105.

  32. Starr P, Verhagen L, Larson P, Bakay E, Taylor R, Cahn-Weiner D, Bartus R, Ostrem J, Marks W: Intrastriatal gene transfer with AAV-neurturin for Parkinson’s disease: Results of a phase I trial. Presented at the 75th Annual Meeting of the American Association of Neurological Surgeons, Washington, D.C., April 16, 2007.

  33. Stover NP, Bakay RA, Subramanian T, Raiser CD, Cornfeldt ML, Schweikert AW, et al. Intrastriatal implantation of human retinal pigment epithelial cells attached to microcarriers in advanced Parkinson disease. Archives of Neurology 2005; 62 (12); 1833-1837.

  34. Ma Y, Tang C, Chaly T, et al. Dopamine cell implantation in Parkinson’s disease: long-term clinical and 18F-FDOPA PET outcomes. Journal of Nuclear Medicine. 2010; 51(1):7–15.

  35. Lang AE, Gill S, Patel NK, Lozano A, Nutt JG, Penn R, Brooks DJ, et al. Randomized controlled trial of intraputamenal glial cell line-derived neurotrophic factor infusion in Parkinson disease. Annals of Neurology 2006; 59 (3); 459-466.

  36. Slevin J.T., Gash, D.A., Gerhardt, GA, Smith, C.D., et al. Unilateral intraputaminal glial cell line-derived neurotrophic factor in patients with Parkinson disease: response to 1 year each of treatment and withdrawal. Neurosurgical Focus, 2006 May 15; 20(5):E1.

  37. Olanow CW, Schapira AH, LeWitt PA, Kieburtz K, Sauer D, Olivieri G, Pohlmann H, et al. TCH346 as a neuroprotective drug in Parkinson's disease: a double-blind, randomised, controlled trial. LancetNeurology 2006; 5 (12); 1013-1020.

  38. Berry AL, Foltynie T. Gene therapy: a viable therapeutic strategy for Parkinson's disease? Journal of Neurology. 2010; 258:179–188.

  39. Marks WJ, Jr., Ostrem JL, Verhagen L, et al. Safety and tolerability of intraputaminal delivery of CERE-120 (adeno-associated virus serotype 2-neurturin) to patients with idiopathic Parkinson’s disease: an open-label, phase I trial. TheLancetNeurology. 2008;7(5):375–376.

  40. Eberling JL, Jagust WJ, Christine CW, et al. Results from a phase I safety trial of hAADC gene therapy for Parkinson disease. Neurology. 2008; 70(21):1980–1983.

  41. Leriche L, Björklund T, Breysse N, et al. Positron emission tomography imaging demonstrates correlation between behavioral recovery and correction of dopamine neurotransmission after gene therapy. Journal of Neuroscience. 2009; 29(5):1544–1553.

  42. Muramatsu SI, Fujimoto KI, Kato S, et al. A phase I study of aromatic L-amino acid decarboxylase gene therapy for Parkinson’s disease. Molecular Therapy. 2010; 18:1731–1735.

  43. Wichmann T, Delong MR: Deep brain stimulation for neurologic and neuropsychiatric disorders. Neuron 52:197–204, 2006.




2020     |     www.medigraphic.com